Covered recipient · General Payments record
CAMERON BRIAN NABAVI
Allopathic & Osteopathic Physicians Ophthalmology
General Payments · PY2018–2024
$2,364.09
- Reported across 108 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $302.16 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $135.01 | 8 |
| BIOTISSUE HOLDINGS INC. | $80.44 | 4 |
| Bausch & Lomb Americas Inc. | $20.62 | 1 |
| RxSight Inc | $19.60 | 1 |
| Dompe US, Inc. | $19.16 | 1 |
| Merz Pharmaceuticals, LLC | $14.20 | 1 |
| ANI Pharmaceuticals, Inc. | $13.13 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.24 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105090839 | CMS |
| ABBVIE INC. | $20.08 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105090841 | CMS |
| ABBVIE INC. | $18.14 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105090843 | CMS |
| ABBVIE INC. | $14.88 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105090845 | CMS |
| ABBVIE INC. | $16.81 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105090847 | CMS |
| ABBVIE INC. | $12.46 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105090849 | CMS |
| ABBVIE INC. | $11.97 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105090851 | CMS |
| ABBVIE INC. | $27.43 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105090853 | CMS |
| ANI Pharmaceuticals, Inc. | $13.13 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091160232 | CMS |
| Bausch & Lomb Americas Inc. | $20.62 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140316398 | CMS |
| BIOTISSUE HOLDINGS INC. | $17.37 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148776391 | CMS |
| BIOTISSUE HOLDINGS INC. | $18.25 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148766832 | CMS |
| BIOTISSUE HOLDINGS INC. | $22.41 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148757521 | CMS |
| BIOTISSUE HOLDINGS INC. | $22.41 | 11/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148786029 | CMS |
| Dompe US, Inc. | $19.16 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151399198 | CMS |
| Merz Pharmaceuticals, LLC | $14.20 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137947498 | CMS |
| RxSight Inc | $19.60 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144222766 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.